Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells., PMID:21076471
Identification of endothelial cell junctional proteins and lymphocyte receptors involved in transendothelial migration of human effector memory CD4+ T cells., PMID:21191062
[Human CD96 gene cloning, expression and identification]., PMID:21764703
Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96., PMID:22879978
Strategies for purging CD96+ stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia., PMID:23894710
[Expression, crystallization and crystallographic study of the 1st IgV domain of human CD96]., PMID:24010363
T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis., PMID:24319005
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy., PMID:26787820
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy., PMID:27620276
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells., PMID:28138156
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy., PMID:28258695
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes., PMID:29133290
CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity., PMID:29721390
Coming of Age: CD96 Emerges as Modulator of Immune Responses., PMID:29868026
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells., PMID:30250471
Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn's disease., PMID:31043678
NK Cell Dysfunction and Checkpoint Immunotherapy., PMID:31552017
CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses., PMID:32043568
Targeting the "PVR-TIGIT axis" with immune checkpoint therapies., PMID:32489646
[Inhibition of CD96 enhances interferon-γ secretion by natural killer cells to alleviate lung injury in mice with pulmonary Chlamydia muridarum infection]., PMID:32895152
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML., PMID:33085758
Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes., PMID:33220589
An obstructive role of NK cells on metastatic growth of clear-cell sarcoma cells in a xenoplant murine model., PMID:33262889
Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy., PMID:33298247
T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer., PMID:33686787
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis., PMID:33687987
Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis., PMID:34186238
Differential impacts of TNFα inhibitors on the transcriptome of Th cells., PMID:34301319
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer., PMID:34503073
Antibody blockade of CD96 by distinct molecular mechanisms., PMID:34595996
Crohn's Disease and Early Exposure to Thiopurines are Independent Risk Factors for Mosaic Chromosomal Alterations in Patients with Inflammatory Bowel Diseases., PMID:34751398
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer., PMID:35292828
Emergence of the CD226 Axis in Cancer Immunotherapy., PMID:35812451
Abnormal expression of CD96 on natural killer cell in peripheral blood of patients with chronic obstructive pulmonary disease., PMID:35866671
Fcγ receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies., PMID:35998045
Natural killer cell profiles in recurrent pregnancy loss: Increased expression and positive associations with TACTILE and LILRB1., PMID:36004818
Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96., PMID:36140247
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives., PMID:36154551
An Inhibitory Role for Human CD96 Endodomain in T Cell Anti-Tumor Responses., PMID:36672244
The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity., PMID:36944702
Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis., PMID:37075705
Twenty-four-color full spectrum flow cytometry panel for minimal residual disease detection in acute myeloid leukemia., PMID:37533738
Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT., PMID:37675979
Poliovirus receptor inhibition in breast cancer cells induces antitumor immunity via T cell activation., PMID:38187056
Natural killer cell subsets and their functional molecules in peripheral blood of the patients with breast cancer., PMID:38652012
Platelet-mediated circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT., PMID:38779918
The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators., PMID:38928307
Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn's disease patients., PMID:39959979
Deep immunophenotyping reveals circulating activated lymphocytes in individuals at risk for rheumatoid arthritis., PMID:40091833
Predictors of Immunogenicity and Loss of Response to ANTI-TNFα Therapy in Crohn Disease-A Systematic Review., PMID:40338684
For research use only. Not for human or drug use.
